AcclaimIP-ad

Match Document Document Title
5831022 Purification of recombinant human IL-1α  
A process for the production of essentially homogeneous soluble, stable, endotoxin free human recombinant interleukin-1α of enhanced specific activity is described. The process involves breaking...
5831000 Hybrid calcitonin  
The improved hybrid calcitonin has a peptide segment in human calcitonin and a peptide segment in calcitonin derived from animals other than humans, such as eel, salmon and chicken. Each of the...
5827826 Compositions of human endothelial cell growth factor  
The present invention is directed to compositions comprising endothelial cell growth factor, an acceptable carrier and, optionally, an extracellular matrix protein, a glycosaminoglycan or serum...
5820845 Somatostatin-derived peptides for imaging and therapeutic uses  
This invention relates to therapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to...
5817486 Recombinant human interleukin-3 (IL-3) multiple mutation polypeptides  
The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid...
5814486 Herpes simplex virus glycoprotein D variants  
The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are...
5807991 Human interleukin-5 receptor  
The invention provides an isolated cDNA sequence coding for murine interleukin 5 receptor, murine secretory interleukin 5 receptor, human interleukin 5 receptor, and human secretory interleukin 5...
5804190 Recombinant vaccine for porcine pleuropneumonia  
This invention discloses the DNA sequences coding for the Actinobacillus pleuropneumonia hemolysin(s). It further discloses a method of producing the A. pleuropneumoniae hemolysin(s) from...
5801145 Method for selectively purging CD77+ cells from bone marrow  
A method for the selective purging ex vivo of CD77 positive cells from bone marrow prior to autologous transplantation is described. The method involves treating the bone marrow with shiga toxin...
5801056 Nucleic acid encoding HIV-1 tat protein  
Nucleic acid encoding a functional HTLV-III/LAV (HIV-1) protein having trans-activating ability, and expression vectors comprising this nucleic acid are described.
5795569 Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation  
Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands or thrombopoietin, that have a biological activity of...
5792746 Aza cyclohexapeptide compounds  
Ceretain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.
5792460 Modified glycoprotein hormones having a CTP at the amino terminus  
"Partial" and "complete" CTP units are used to modify biologically active proteins and peptides to alter their clearance patterns. "Complete" CTP units have the amino acid sequence found at...
5792466 Mimetic insect kinin analogs for insect control  
Novel pseudopeptide analogs of the insect kinin neuropeptide family which possess biological activity mimicking that of the naturally occurring neuropeptides are disclosed. By substituting a...
5792450 Purified human CSF-1  
The present invention relates to the purification of proteins, to the products of such purification, and to DNA probes constructed therefrom. More specifically, the invention relates to the...
5789552 Interleukin-6 receptor antagonists  
Disclosed are interleukin-6 receptor antagonists. These receptor antagonists are generated by mutating amino acid positions 31, 35, 118, 121, 175, 176 and/or 183 of human interleukin-6.
5786325 Cyclic peptide antifungal agents and methods of making and using  
Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I ##STR1## where: R', R", R'", Rx1, Rx2, Ry1, Ry2, Ry3, Ry4, and R0...
5783666 APC (adenomatous polyosis coli) protein  
A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous...
5773582 Tumor necrosis factor muteins  
Muteins of human tumor necrosis factor (hTNF), a process for production thereof, and DNAs encoding these muteins are found to have a superior antitumor activity and lower acute lethal toxicity...
5766581 Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation  
Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands), that have a biological activity of stimulating the...
5767067 Follicle stimulating hormone and pharmaceutical compositions containing same  
Purification of human FSH from post-menopausal urine gonadogropin using immunochromatography and reverse phase HPLC steps yelds a biologically active hormone which is free from detectable traces...
5763578 All-trans retinaldehyde binding protein, and antibodies thereto  
An isolated DNA molecule encodes a photoreceptive retinaldehyde-binding protein of the visual system and brain. The isolated protein is a putative receptor for an all-trans-retinylidene...
5759818 N-terminal CTP extended pharmaceutical peptides and proteins  
"Partial" and "complete" CTP units are used to modify biologically active proteins and peptides at the aminoterminus to alter their clearance patterns. "Complete" CTP units have the amino acid...
5760000 Inhibition of liver cancer by the use of GnRH and GnRH analogs  
The invention provides a method for treating liver cancer in a mammal comprising administering to the mammal an inhibitory effective amount of at least one GnRH-related compound. Pharmaceutical...
5756328 Acyltransferase and cDNA encoding acyltransferase  
Essentially pure acyltransferase is provided which is functional to catalyze reaction to form sugar esters. Also provided is isolated gene encoding acyltransferase. Additionally provided is method...
5756458 Stabilized potent GRF analogs  
Novel GRF PEPTIDES having Thr, Val or Ile at position 2, having an amino acid selected from the group consisting of Ala, Val, Leu, Ile or Gly at position 15, and optionally substituted with Val or...
5750652 Deltex proteins  
The present invention relates to amino acid sequences of the encoded deltex protein. The invention further relates to fragments and other derivatives, and analogs, of deltex proteins. In specific...
5750509 Amide derivatives of antibiotic A 40926  
The present invention is directed to novel antibiotic A 40926 derivatives characterized by having a carboxy, (C1 -C4) alkoxy-carbonyl, aminocarbonyl, (C1 -C4) alkylaminocarbonyl, di (C4...
5747324 Self-assembled, defective, non-self-propagating lentivirus particles  
The present invention provides recombinant DNA viral vectors which co-express lentivirus genes encoding structural and enzymatic polypeptides capable of assembling into defective...
5744450 GnRH analogs  
Peptides which include unnatural amino acids and which either promote or inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads....
5736509 Cyclic peptide surface feature mimics of endothelin  
Cyclic peptides and pharmaceutically acceptable salts and esters thereof are provided. The cyclic peptides and pharmaceutically acceptable salts and esters thereof mimic surface features of the...
5736391 HIV gp41 mutants  
Nucleic acid constructs encoding mutated human immunodeficiency virus gp41 polypeptides are described. The mutated polypeptides are effective to disrupt viral replication of HIV or disrupt the...
5734019 Hepatitis C virus antigen polypeptide, production method therefor, and antibody detection method  
A hepatitis C virus antigen polypeptide having a molecular weight of approximately 22 kilodaltons expressed from a hepatitis C virus structural gene region; a production method for a hepatitis C...
5731408 Peptides having potent antagonist and agonist bioactivities at melanocortin receptors  
Cyclic lactam peptides, seven amino acids in length, having D-2'-naphthylalanine (D-2'-Nal) or D-para-iodo-phenylalanine D-(p-I)Phe at position 4 of the peptide provided potent and specific...
5730984 Vaccine against helminth infection comprising Sm-14 fatty acid binding protein of Schistosoma mansoni  
The present invention relates to helminthic derived antigenic material capable of inducing effective and long lasting protection against parasites, in particular to antigens that mediate...
5723585 Method of purifying cardiac hypertrophy factor  
Isolated CHF, isolated DNA encoding CHF, recombinant or synthetic methods of preparing CHF, and a method of purifying CHF are disclosed. These CHF molecules are shown to influence hypertrophic...
5723165 Aspartyldipeptide derivatives and sweetener compositions containing the same  
Aspartyldipeptide compounds of the formula (I) L-Asp-X-NH-C*R1 R2 (I)where R1 is alkyl or alkoxymethyl, R2 is phenyl, benzyl, cyclohexyl or cyclohexylmethyl, C* has an (S) configuration when R1 is...
5714467 Antibacterial and antimalarial hybrid peptides  
The invention relates to antibacterial and antimalarial peptides which are hybrids peptides which a of naturally occurring peptides such as cecropins, attacins, magainins, sarcotoxin, sapecin,...
5707629 Immunogenic composition against equine herpesvirus type 1  
The present invention is directed to a gene encoding an envelope glycoprotein of equine herpesvirus type 1 (EHV-1), the glycoprotein D (gD) gene, its gene product and antibodies directed against...
5707864 Nucleic acids encoding mutated human immunodeficiency virus matrix proteins  
Nucleic acid constructs encoding mutated human immunodeficiency virus matrix proteins are described. The mutated proteins lower the incorporation of envelope polypeptides in viral particles,...
5705609 Decorin fragments inhibiting cell regulatory factors  
The present invention provides a method of inhibiting an activity of a cell regulatory factor comprising contacting the cell regulatory factor with a purified polypeptide, wherein the polypeptide...
5703043 Bone morphogenetic protein-10 (BMP-10) compositions  
Purified Bone Morphogenetic Protein-10 (BMP-10) proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-10 proteins are also disclosed. The proteins may be used in...
5700911 Bone morphogenetic protein -11 (BMP-11) compositions  
Purified Bone Morphogenetic Protein-11(BMP-11) proteins and processes for producing them are disclosed. Recombinant DNA molecules encoding the BMP-11 proteins are also disclosed. The proteins may...
5698518 Method for regulating inflammation and tumor growth with calmodulin, calmodulin analogues or calmodulin antagonists  
A method of treating patients to inhibit inflammation is disclosed. In the method, an effective amount of calmodulin, a calmodulin analogue or calmodulin receptor agonist is administered to a...
5698516 Biologically active vasopressin analogues  
Vasopressin analogues of formula (I) ##STR1## wherein X is (S)-2-amino-2-methyl-butanoic acid (CaMeAbu) or Valine (Val), Y is Thienylalanine (Thi) or Methionine (Met), Z is D-Phenylalanine (D-Phe)...
5696083 Personal care composition containing pyrithione and polymyxin  
This invention relates to personal care compositions, and, more specifically, to a composition comprising a pyrithione salt or acid, polymyxin antibiotic, and a suitable carrier. The pyrithione...
5696082 Hydroxamic acid derivatives  
Compounds of general formula (I) wherein X is --CONHOH or --CO2 H, principally characterised by the presence in substituent R3 and/or R4 of a group of formula (II) are inhibitors of matrix...
5696089 Histidine substituted growth hormone releasing factor analogs  
Novel growth hormone releasing factor analogs are presented having the formula: ##STR1## wherein R1 is His, 3-MeHis, desNH2 His, Tyr, or desNH2 Tyr; R2 is Val, Leu, or Ile; R3 is Ala; R4 is Met,...
5696232 Listeria monocytogenes specific proteins, and uses thereof  
The present invention is directed to Listeria monocytogenes specific protein that is encoded by nucleotide sequence of FIG. 1, the complementary sequence of which hybridizes to the nucleotide...
5693779 Production and use of anti-dorsalizing morphogenetic protein  
An isolated polynucleotide of anti-dorsalizing morphogenetic protein (ADMP-1) is obtained from Xenopus. The protein is most closely related to human BMP-3. ADMP-1 functions as a modulator for...